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Abstract
The International Committee of Medical Journal 
Editors (ICMJE) provides recommendations to improve 
the editorial standards and scientific quality of biomedical 
journals. These recommendations range from uniform 
technical requirements to more complex and elusive 
editorial issues including ethical aspects of the scientific 
process. Recently, registration of clinical trials, conflicts 
of interest disclosure, and new criteria for authorship 
‑ emphasizing the importance of responsibility and 
accountability‑, have been proposed. Last year, a new 
editorial initiative to foster sharing of clinical trial data 
was launched. This review discusses this novel initiative 
with the aim of increasing awareness among readers, 
investigators, authors and editors belonging to the Editors´ 
Network of the European Society of Cardiology.
The Editors´ Network of the European Society of Cardiology 
(ESC) is committed to promoting the implementation 
of high‑quality editorial standards among ESC National 
Societies Cardiovascular Journals (NSCJ).1‑4 NSCJ play a 
major role in disseminating high‑quality scientific research. 
However, they also play a relevant role in education and 
harmonization of clinical practice.3 Most NSCJ are published 
in local languages, but many have English editions and have 
gained international scientific recognition.1‑4 NSCJ well 
complements official ESC journals and, altogether, provide 
an effective means to disseminate European cardiovascular 
research. In a globalized and highly competitive editorial 
environment, promoting high quality editorial standards 
remains of paramount importance to increase the scientific 
prestige of NSCJ.1‑4 From its conception, the Editors´ 
Network strongly advocated for the adherence to the uniform 
recommendations of the International Committee of Medical 
Journal Editors (ICMJE).1 In its mission statement document 
the Editors´ Network committed to adapt NSCJ to follow 
these general editorial recommendations.1 However, NSCJ 
are highly heterogeneous in scope and contents and these 
new recommendations should be embraced progressively, 
considering currently existing editorial policies and the 
editorial freedom of the NSCJ.1‑4
Ethical issues play a growing role in ensuring the 
credibility of the scientific process.5‑13 Biomedical research 
relies on trust. However, transparency also represents a 
major tenet in the scientific process.5‑8 This review will 
discuss the new editorial recommendations on data sharing 
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issued by the ICMJE.14 Novel ICMJE recommendations 
always appear as provocative, and often as too ambitious, 
when initially presented. Moreover, implementation of 
editorial changes is rather demanding from a technical 
and logistical viewpoint. Adherence to novel editorial 
initiatives is challenging not only for editors, but also for 
the entire scientific community. Therefore, many Editors 
have a natural tendency to avoid stepping ahead as 
early adopters of new editorial experiments and usually 
prefer to keep moving within their comfort zone until 
the sea change has matured.1‑4 However, experience has 
taught us that all editorial initiatives developed by the 
ICMJE eventually prevailed and played a critical role in 
maintaining the credibility of the scientific process.9‑13 
Highly successful recent examples include trial registration, 
a conflicts of interest initiative and the new requirements 
for authorship.9‑13
The novel ICMJE recommendations on data sharing14 
are discussed herein from a didactic perspective with the 
aim to provide new editorial insights and, hopefully, to be 
progressively adopted and implemented by the NSCJ.
Sharing clinical trial data: the new ICMJE proposal
The ICMJE considers that there is a moral obligation to 
responsibly share the data generated by clinical trials.14 
The rationale underlying this global endeavor is that 
patients have assumed a risk by accepting to participate 
in a trial. Accordingly, making the obtained data publicly 
available represents a responsible initiative to facilitate the 
advancement of science. Sharing the data would increase 
trust in the conclusions reached by trials. Indeed, data 
sharing allows confirmation of the results by independent 
research.14 Furthermore, new hypotheses may be pursued 
by different groups of investigators. This initiative may foster 
the leveraging of data to answer different research questions 
not contemplated in the original study. If science becomes 
an open process, then many researchers would benefit by 
taking advantage of reliable data generated somewhere else. 
Therefore, data sharing emerges as the best way to ensure 
that all the information gathered by trials is made freely and 
widely available, so that it can be readily used to advance 
scientific knowledge.14 The use of previously collected data to 
further advance science is difficult to criticize. As discussed, 
this honours the volunteerism of the patients who signed up 
and consented to participate in a trial.
Governments, funding agencies, scientific societies, the 
industry and even the lay society growingly demand sharing 
clinical trial data. Therefore, the ICMJE suggests that editors should 
help to meet this ethical obligation by devising new editorial 
policies specifically addressing this issue.14 Proponents of open 
science should be pleased by this new editorial requirement of 
sharing clinical trial data.14
The first consideration is to clarify what a clinical trial is 
exactly. According to the ICMJE definition, a clinical trial is 
a study that prospectively assigns people to an intervention 
in order to assess the cause‑and‑effect relationship between 
that intervention and the ensuing health outcome.5
The ICMJE considers that sharing de-identified individual 
patient data should become part of the publication process of 
clinical trials.14 This strategy protects patient´s confidentiality 
rights. The requirement, however, is restricted to the 
individual‑patient data underpinning the results presented in 
the published article. Importantly, a clear plan for data sharing 
should be disclosed at the time of initial trial registration 
and should be also presented at the time of manuscript 
submission. The proposal requires clinical trialists to declare 
that they will share their data publically as a prerequisite for 
publishing the trial.14 They should promise to freely release 
individual patient raw data at the time they submit the 
manuscript for consideration.
It is important to keep in mind that clinical trial registration 
was a previous ICMJE editorial initiative aimed to address 
problems related to publication bias (selective publication 
of positive trials), endpoints inconsistency and redundant 
research.9,10 Potentially, public repositories provide an 
optimal tool not only for initial trial registration but also 
for individual‑patient data sharing. From now on the plan 
for data‑sharing would be an important step of the clinical 
trial registration initiative.9,10,14 Details on whether the data 
would be freely available upon request, or only after a 
formal application that eventually will be approved after 
an agreement is reached on data use conditions, should be 
presented. Finally, it has been proposed that the data should 
be made public no more than 6 months after publication 
of the original study in the journal.9,10,14 Clinicaltrials.com, 
a widely used non‑for profit scientific repository,9,10 has 
already adapted its registration platform to specifically clarify 
data‑sharing plans at the time of clinical trial registration.
Obviously, this editorial initiative may have profound 
consequences on the planning, conduction and reporting of 
clinical trials and, in fact, may deeply influence research and 
publication strategies.14 As a result, the idea is to implement this 
requirement for any clinical trial that begins to enroll patients 
1 year after the official adoption of this editorial policy by the 
corresponding journal.14 The initiative will also have major 
implications for the editorial process. Indeed, Editors are 
supposed to monitor the data sharing process and, eventually, 
address potential irregularities. These might include requests of 
clarification to the authors, notification to academic institutions, 
publication of expressions of concern or even retractions.
Finally, the ICJME acknowledges that the rights of the 
investigators and sponsors should be protected.14 Moreover, credit 
to the original report should be granted by including a unique 
identifier of the data set. It is emphasized that credit should be 
always given to the original investigators that posted the data 
after publication of their research. Furthermore, additional 
investigators using these databases should request collaboration 
of the investigators that originally collected the data to ensure 
adequate data interpretation, management and analysis.
Challenges of data sharing
Although it appears clear that this initiative will further 
improve transparency and the overall integrity of the scientific 
literature, some remaining issues need to be addressed. 
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There is inherent resistance to embrace open science initiatives 
from some academic institutions or investigators that defend 
the idea of exploiting their own data.15,16 Until now clinical 
researchers were discouraged from working with clinical trial 
data they did not generate themselves.15,16 Likewise, trialists 
tended to see trial data as their personal property and would 
routinely refuse requests for data sharing. In fact, until very 
recently most researchers and pharmaceutical industry 
groups were opposed to making raw data available after trial 
publication. This practice, however, differs from other disciplines 
(as genomics or economics) where data sharing has been 
common place for a long time.15,16
Obtaining reliable, high‑quality original data requires a major 
research effort. Allowing a sufficient period of time from the time 
of article publication to the need to share the raw data would 
give original investigators the possibility of publishing additional 
subgroup analyses from their own data.14 This new proposal 
will further increase the pressure on academic investigators 
that frequently do not have the required resources to publish 
their subsequent analyses and require time to prepare the new 
manuscripts.14 Notably, most researchers have no experience 
with the process of releasing or dealing with public data. 
Furthermore, the effort and resources required to organize 
the raw data in a way that would be comprehensible to other 
investigators remain a cause of major concern.14 This would 
require technical support and adequate funding.
Data‑access to non‑trial researchers may disclose problems 
not recognized by the initial investigators. Although this will 
increase transparency and, therefore, trust in trial results, it might 
also generate confusion and undue scientific controversies. It 
is difficult to envision how the new researchers will gain the 
required detailed knowledge of the complicated datasets enjoyed 
by the original trial investigators.14 A reliable assessment of the 
data requires a deep knowledge on the study background and 
to be able to properly address many nuances and practical 
considerations. These include precise information on the way 
variables were defined, how data was collected and how results 
were finally coded and entered into the database. The initiative 
might be fraught with problems related to incorrect analysis 
resulting in inaccurate results and erroneous interpretations, 
potentially damaging science.14
Finally, Editors, already deluged with work, will need to check 
that all of the raw data of the published articles eventually has 
been released as promised. Different results may emerge from 
misconceptions regarding what data should be analysed to 
answer specific questions.14 If there are differences in results, 
it will be difficult to decide which analysis provides the most 
accurate reflection of the data. This could generate undue 
scientific noise, with contradictory results and rectifications, 
which may generate confusion and frustration in the scientific 
community. Finally, this may also promote the simultaneous 
publication in several journals of conflicting results from the 
same database by different groups.14 
As many issues still should be clarified, the ICMJE asked 
for feedback on its preliminary editorial proposal on clinical 
trial data sharing.14 Obviously, the initiative will only gain 
the required maturity from the experience gained during its 
adoption and implementation.
Previous initiatives on data sharing
Several leading academic entities previously have worked 
in this field. The British Medical Journal pioneered an editorial 
initiative of data sharing.17 In 2012 this policy took effect only 
for trials on drugs and devices but, in 2015, the requirement of 
data sharing on request was extended to all submitted clinical 
trials.17 It has been proposed that individual patient data may 
also be of major value during the peer review process by 
permitting independent verification of the results before final 
publication.18 Although this initiative might be of potential 
value most reviewers are already deluged with work and this 
extra task could generate fatigue and burn out phenomena. 
In addition, many good clinical reviewers do not have the 
expertise required to manage data and to perform confirmatory 
statistical analyses.18 Some journals, as JAMA, previously 
developed some related editorial initiatives including the 
request for independent statistical analyses by an academic 
statistician of industry‑sponsored trials.19
The World Health Organization (WHO) and the Institute 
of Medicine (IOM) previously made important declarations 
on clinical trial transparency. In this regard, the IOM issued 
specific guidelines for trial data sharing.20 WHO initially 
presented a statement on public disclosure of clinical trial 
results and, subsequently, encouraged sharing of research 
datasets whenever appropriate.21‑23 More recently, the WHO 
developed global norms for sharing data and results during 
public health emergencies, with special focus on clinical, 
epidemiologic, and genetic features of new infectious diseases 
and experimental therapeutics and vaccines. In emergency 
situations, data needs to be shared quickly before the 
information is formally published.23 
Finally, the National Heart, Lung and Blood Institute (NHLBI) 
presented detailed data‑sharing practices allowing public access 
to trial raw data and developed a data repository currently 
including over half a million patients from over 100 trials and 
observational studies.24 In 2015 the NHLBI discussed its intent 
to make public the digital data from its funded trials.24 
Platforms and repositories
Up to 30,000 clinical trials are conducted annually 
worldwide generating a huge volume of patient‑level 
raw data.25 Currently, however, available portals for data 
sharing are still not adequate. Most of them require a 
time consuming request, including a detailed research 
proposal with the study design, main endpoints and a 
statistical plan.25 The submitted proposal is then reviewed 
by an independent research panel that decides whether to 
approve the request for data.21,25,26 Currently, this process 
takes too long and when eventually the data is obtained 
oftentimes it is not readily usable.25 However, the means to 
facilitate data sharing from the data holder to the researcher 
may be cumbersome and challenging to implement. 
Some systems provide an electronic form or template.21 
Nevertheless, when these are not available, a de novo 
proposal should be generated outlining the purpose, the 
statistical analysis plan, the research team, and potential 
conflicts of interest. The review process may come from 
an internal or external review panel selected by the data 
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holder or by a third party.25‑27 Finally, data can be shared 
through a public website or by direct communication 
between the data holder and the researcher. In most cases, 
however, controlled access is required. Before any analysis 
is started, reviewing all the accompanying documentation 
to assist the researcher in the understanding of the original 
clinical trial and the methodology used remains critical. 
Furthermore, the data holder may require a legally binding 
data sharing agreement and should be available to provide 
the required support should questions arise.27
Major care should be taken to prevent the perils that may 
undermine the value of data sharing.14 Data from trials should 
be responsibly used.28 A recent survey from UK Clinical 
Trial Units disclosed some potential risks associated with 
data sharing.29 These basically included a) misuse of data, 
b) incorrect secondary analyses, c) resource requirements and 
d) identification of patients.29,30 Researchers are responsible for 
presenting the data in a format amenable for external secondary 
use. Repositories should be prepared to make raw data available 
in standardized platforms in a fully comprehensive manner. 
Data sharing from trials with anonymized patient‑level data 
with associated metadata and supporting information should be 
made available to other researchers following an independent 
analysis of the research proposals. Developing and adopting 
standard approaches to protecting patient privacy are urgently 
required.14 Finally, an adequate infrastructure should be 
organized to support effective data sharing. In this regard, the 
role of the industry is significantly growing as demonstrated by 
some joint initiatives, such as the Yale University Open Data 
(YODA) project.16,31
Some academic research organization consortiums 
particularly focussed on the study of cardiovascular 
diseases,32 have developed interesting tools for data sharing. 
This cardiovascular initiative requires presentation of a 
standardized request in a Web portal. Proposals are to be 
analyzed by a scientific committee, including members 
designated by the consortium and a statistician along with the 
trial’s principal investigator. The idea is to ensure an adequate 
use of the data base and correct statistical analyses, while 
averting the problem of multiple investigators proposing the 
same analyses.32
 
Statistical issues
Statisticians play a key role in developing data sharing 
strategies.19 They should be involved from the very 
beginning to organize the research strategy and the required 
analytical techniques.19 In this scenario statisticians should 
move from their classical role as data gate‑keepers to 
that of data facilitators.19 A data sharing working group of 
medical research statisticians has been recently created 
from the pharmaceutical and biotechnological industry 
and from academia. The idea was to address the technical 
and statistical challenges of accessing research data for 
re‑analyses. Specific techniques are required to ensure 
adequate data manipulation to convert the data initially 
collected and entered in the data base into data that is 
analytically usable. Converting raw data into standardized 
formats may be challenging. Moreover, familiarity with 
the required statistical programing language is necessary. 
Independent statisticians should play a major role in guiding 
the principles of re‑analysis based on the researchers´ 
request while, at the same time, guarding against misleading 
conclusions. They should be fully aware that additional 
analysis may yield different results compared with the 
original analyses. Accordingly, they should be prepared to 
face criticism but, at the same time, they should be able to 
openly challenge previous statistical methods.19
Statistical guidance may be required for appropriate 
interpretation of results from re‑analyses where different methods 
have been utilized. In particular, it is important to keep in mind 
the inherent risk of over‑interpretation of the results from multiple 
subgroup analyses.33 Likewise, documents for best practices in 
data anonymization have been developed.34 Statisticians should 
be also familiar with this methodology. Risk to patient privacy 
can be mitigated by data reduction techniques. Data holders 
are responsible for generating de‑identified datasets to offer 
protection for patient privacy through masking or generalization 
of main identifiers. In addition, legally binding data sharing 
agreements should include a compromise not to attempt to 
identify patients.34 In particular, it is recommended that data 
use agreements are signed by the data holder and researchers. 
Only appropriately qualified named researchers should be 
granted access to the data. Finally, high security levels should be 
implemented for data transferring. Resources, costs and effort 
required to make patient‑level data available for third party 
research may be considerable and, therefore, adequate funding 
should be organized.34
Credit to the original authors
A clear motivation for researchers to conduct randomized 
clinical trials is the opportunity to publish different studies in 
addition to the main manuscript with the primary endpoint. 
These secondary analyses may be of major value to unravel new 
findings from the original dataset.35,36 Many have proposed that 
the time to open the process of data sharing should be extended 
to 2 years, or even to 5 years in selected complex or large 
studies. This will allow a precious time for original investigators 
to further scrutinize and analyze in depth their own data. 
As blinding is necessary during trial execution, once the study 
is completed the research teams concentrate on publishing the 
primary findings as soon as possible. Following this, usually there 
is a series of pre‑planned additional analyses. These studies 
are organized by collaborative research teams from different 
institutions, but usually with relatively poor support. Secondary 
analyses are also very important for co‑investigators and junior 
scientists. To respect this legitimate interest an extension from 
the 6 month‑period after the primary data has been published 
has been advocated.35,36
Academia rewards scientists with recognition for making 
their discoveries public. Credit should be granted to the 
original researchers that create data sets that other investigators 
find useful.14,15 Otherwise, original investigators may be 
tempted to consider research parasites those performing 
secondary analyses of their data. Furthermore, mechanisms are 
required to ensure that the external analyses are conducted 
adequately and not merely to undermine the original 
findings. Direct collaboration between primary and secondary 
researchers is, therefore, necessary to ensure proper data 
393
Special Article
Alfonso et al
Data Sharing
Arq Bras Cardiol. 2017; 108(5):390-395
1. Alfonso F, Ambrosio G, Pinto FJ, Van der Wall EE, Kondili A, Nibouche 
D, et al; Grupo de trabajo de la Sociedad Europea de Cardiología. 
[European National Society cardiovascular journals. Background, 
rationale and mission statement of the “editors’ club”]. Rev Esp Cardiol. 
2008;61(6):644‑50. 
2. Alfonso F, Ambrosio G, Pinto FJ, Ector H, Vardas P, Kulakowski P, et 
al; Editors’ Network ESC Task Force. European Society of Cardiology 
national cardiovascular journals: the ‘Editors’ Network’. Eur Heart J. 
2010;31(1):26‑8.
3. Mills P, Timmis A, Huber K, Ector H, Lancellotti P, Masic I, et al. The role of 
European national journals in education. Heart. 2009;95(24):e3.
4. Alfonso F. The Editors’ Network of the European Society of Cardiology. Eur 
Heart J. 2011;32(8):919‑21.
5. International Committee of Medical Journals Editors. Recommendations 
for the Conduct, Reporting, Editing, and Publication of Scholarly Work 
in Medical Journals. (Updated December 2015). [Cited in 2016 May 10]. 
Available from: http://www.icmje.org
6. Council of Science Editors. White Paper on Publication Ethics. CSE’s White 
Paper on Promoting Integrity in Scientific Journal Publications, 2012 
Update. (Updated 2012). [Cited in 2015 Jan 10]. Available: http://www.
councilscienceeditors.org
7. World Association of Medical Editors. WAME Professionalism Code 
of Conduct The new WAME Professionalism Code of Conduct for 
medical journal editors. [Cited in 2013 Jan 12]. Available: http://www.
publicationethics.org/resources/ethics‑resources
8. Committee On Publication Ethics. COPE. Code of Conduct and Best Practice 
Guidelines for Journal Editors. [Cited in 2013 Jan 12]. Available from: http://
publicationethics.org/resources/guidelines
9. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al; 
International Committee of Medical Journal Editors. Is this clinical trial fully 
registered?‑‑A statement from the International Committee of Medical 
Journal Editors. N Engl J Med. 2005;352(23):2436‑8.
10. Alfonso F, Segovia J, Heras M, Bermejo J. [Publication of clinical trials in 
scientific journals: editorial issues]. Rev Esp Cardiol. 2006;59(11):1206‑14.
11. Drazen JM, Van der Weyden MB, Sahni P, Rosenberg J, Marusic A, Laine C, 
et al. Uniform format for disclosure of competing interests in ICMJE journals. 
N Engl J Med. 2009;361(19):1896‑7.
12. Alfonso F, Timmis A, Pinto FJ, Ambrosio G, Ector H, Kulakowski P, et al; Editors’ 
Network European Society of Cardiology Task Force. Conflict of interest 
policies and disclosure requirements among European Society of Cardiology 
National Cardiovascular Journals. Eur Heart J. 2012;33(5):587‑94.
13. Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, Højgaard 
L, et al. Sponsorship, authorship, and accountability. N Engl J Med. 
2001;345(11):825‑6.
14. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen 
JM, et al. Sharing Clinical Trial Data‑‑A Proposal from the International 
Committee of Medical Journal Editors. N Engl J Med. 2016;374(4):384‑6.
15. Merson L, Gaye O, Guerin PJ. Avoiding data dumpsters‑‑toward equitable 
and useful data sharing. N Engl J Med. 2016;374(25):2414‑5.
16. Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) Project‑
‑A Mechanism for Data Sharing. N Engl J Med. 2016;375(5):403‑5.
17. Loder E, Groves T. The BMJ requires data sharing on request for all trials. 
BMJ. 2015;350:h2373.
18. Kavsak PA. The International Committee of Medical Journal Editors proposal 
for sharing clinical trial data and the possible implications for the peer review 
process. Ann Transl Med. 2016;4(6):115.
19. Manamley N, Mallett S, Sydes MR, Hollis S, Scrimgeour A, Burger HU, et al. 
Data sharing and the evolving role of statisticians. BMC Med Res Methodol. 
2016;16 Suppl 1:75.
20. Institute of Medicine. Sharing clinical trial data: maximizing benefits, 
minimizing risk. Washington, DC: The National Academies Press; 2015.
21. Vallance P, Freeman A, Stewart M. Data sharing as part of the normal 
scientific process: a view from the pharmaceutical industry. PLoS Med. 
2016;13(1):e1001936.
22. World Health Organization. (WHO). International clinical trials registry 
platform (ICTRP). [Cited in 2015 Jan 10]. Available from: www.who.int/
ictrp/results/reporting/en/
References
analysis and interpretation.14,15 The original investigators that 
designed and conducted the trial and obtained sources of 
founding deserve to receive the adequate scientific credit.28 
Conclusions
The data transparency revolution is here to stay. This is 
just another step ahead into a culture of open science 
and it is clear that we are at the dawn of a new age.37,38 
Several European National Societies have already developed 
registry programs in which the registries databases are 
public for the use of their members.39 Major challenges 
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